Project Grant K01HL175188
Award Date 9/18/25
Completion Date 8/31/30
Dollars Obligated $170K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- This $285,195 project grant was awarded on August 20, 2025 by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc. to support research on improving hypertension management through patient self-titration of antihypertensive medications. The project aims to adapt this intervention to the U.S. primary care context by assessing patient preferences, provider perspectives, and integration with electronic health records and...
- The National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), awarded a $688,525 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, San Diego (UCSD). The grant, titled "Blood Pressure Control Advancing Refugee Health Equity (BPCARE): An RCT of Adherence", aims to develop and test a behavioral intervention to improve antihypertensive medication adherence and blood pressure...
- The Project Grant award of $692,846.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) will fund the "Better Heart Study" at the University of Pennsylvania. The study aims to utilize behavioral science strategies to increase hypertension diagnosis and treatment in India, where hypertension prevalence remains high and many individuals are undiagnosed or not receiving care. The project will test two scalable behavioral...
- The University of Colorado-Denver received a $553,217 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on August 15, 2025. The grant supports research on the "HAT-Dependent Control of Cardiac Fibrosis" to investigate the role of epigenetic regulatory proteins in controlling the activation of cardiac fibroblasts and development of cardiac fibrosis, which contributes to diastolic dysfunction and heart failure. The...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $191,777 Project Grant to the University of California, Davis (UC Davis) to support the research project "Translating Individual-Level Risks and Preferences into Personalized Blood Pressure Target Decisions". The 5-year project, led by Dr. Simon Ascher, aims to develop expertise in advanced statistical methods, patient preference assessment, and...
- This federal Project Grant award of $130,065 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to conduct systematic economic analyses on the costs associated with implementing a chronic care model for patients with hypertension. The grant supports a study led by principal investigator Dr. Elaine Khoong and collaborators Dr. Dhruv Kazi, Dr. Lina Tieu, and Dr. Lisa Ochoa-Frongia. The project aims to...
- The University of Alabama at Birmingham (UAB) received a $222,750 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to develop a clinical decision support questionnaire to identify barriers to blood pressure control. The project aims to address the high rates of uncontrolled hypertension in the U.S., which is a leading cause of morbidity, mortality, and substantial healthcare costs. The award, with a performance period from July...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $189,000 Project Grant under CFDA #93.837 Cardiovascular Diseases Research program to the University of Colorado-Denver. The 2-year grant, with a period of performance from September 15, 2025 to August 31, 2027, will support research to investigate the role of outdoor air pollution and environmental allergens in driving treatment response in children with acute asthma...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,084,359 to Nusirt Sciences, Inc. to conduct clinical validation of the fixed combination drug product NS-0200 for the treatment of hypertension. The award will support research activities from September 15, 2025 through June 30, 2027 to evaluate the efficacy and safety of this novel hypertension treatment. Hypertension is a major global health issue, affecting...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $234,000 Project Grant to the University of Colorado-Denver. This 2-year grant, effective August 1, 2025 through July 31, 2027, will support secondary analysis of noninvasive imaging biomarkers to predict the early onset of single ventricle heart disease (SVD) failure. The research aims to quantify systemic and pulmonary vascular compliance through...